↑ 疾患リストへ ← 戻る

 8. ハンチントン病 [臨床試験数:110,薬物数:125(DrugBank:50),標的遺伝子数:87,標的パスウェイ数:146] 

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04102579November 201911 November 2019Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington's DiseaseA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington's DiseaseChorea, HuntingtonDrug: Valbenazine;Drug: PlaceboNeurocrine BiosciencesHuntington Study GroupRecruiting18 Years75 YearsAll120Phase 3United States
2NCT04071639October 20, 201930 September 2019Symptomatic Therapy for Patients With Huntington's DiseaseRandomized Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease PatientsHuntington DiseaseDrug: Haloperidol;Drug: Risperidone;Drug: Zoloft;Drug: Coenzyme Q10Second Affiliated Hospital, School of Medicine, Zhejiang UniversityRecruitingN/AN/AAll100Phase 1China
3NCT04000594September 2, 201922 October 2019A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's DiseaseAn Open-Label, Adaptive Multiple-Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's DiseaseHuntingtons DiseaseDrug: RO7234292 (RG6042)Hoffmann-La RocheRecruiting25 Years65 YearsAll20Phase 1United Kingdom
4NCT03980938July 8, 201929 July 2019Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington DiseaseA Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)Huntington DiseaseDrug: neflamapimod;Other: PlaceboEIP Pharma IncVoisin Consulting, Inc.Recruiting30 Years70 YearsAll16Phase 2United Kingdom
5NCT03842969April 23, 201911 November 2019An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Patients Who Participated in Prior Roche and Genentech Sponsored StudiesAn Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's DiseaseHuntington DiseaseDrug: RO7234292 (RG6042)Hoffmann-La RocheRecruiting25 YearsN/AAll950Phase 3United States;Canada;Germany;Spain;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03854019April 1, 201929 April 2019Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's DiseaseEvaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's DiseaseHuntington Disease;IrritabilityDrug: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg);Drug: PlaceboThe University of Texas Health Science Center, HoustonCures Within ReachRecruiting18 Years75 YearsAll22Phase 3United States
7NCT03787758February 28, 201922 October 2019A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part BA Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's DiseaseHuntington DiseaseDrug: SAGE-718Sage TherapeuticsRecruiting18 Years70 YearsAll10Phase 1United States
8EUCTR2016-005095-10-DK26/02/201930 April 2019A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s DiseaseHuntington's Disease
MedDRA version: 20.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: WVE-120101
Current Sponsor code: WVE-120101
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 8-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Intrathecal use
Wave Life Sciences Ltd.Authorised Female: yes
Male: yes
48Phase 1;Phase 2France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
9NCT03761849January 23, 20194 November 2019A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's DiseaseA Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's DiseaseHuntingtons DiseaseDrug: RO7234292;Drug: PlaceboHoffmann-La RocheRecruiting25 Years65 YearsAll660Phase 3United States;Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;China
10NCT03764215November 15, 201818 December 2018Nilotinib in Huntington's DiseaseAn Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's DiseaseHuntington DiseaseDrug: Nilotinib 150 MGGeorgetown UniversityRecruiting25 Years90 YearsAll10Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2017-002471-25-GB18/10/201828 February 2019An extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the study drug, RO7234292 (ISIS 443139), in patients who participated in prior investigational studies of RO7234292AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN PRIOR INVESTIGATIONAL STUDIES OF RO7234292 (ISIS 443139)Early Manifest Huntington's Disease
MedDRA version: 20.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Code: Ro 723-4292/F02
Pharmaceutical Form: Solution for injection
INN or Proposed INN: n.a.
CAS Number: 1709886-74-7
Current Sponsor code: RO7234292
Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 6-
F.Hoffmann La-Roche LtdNot Recruiting Female: yes
Male: yes
46Phase 1;Phase 2Canada;Germany;United Kingdom
12NCT03575676August 8, 201830 September 2019Efficacy and Safety of SOM3355 in Huntington's Disease ChoreaPhase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements.Huntington's ChoreaDrug: SOM3355 100mg BID;Drug: SOM3355 200mg BID;Drug: Placebo BIDSOM Biotech SLNot recruiting18 YearsN/AAll32Phase 2Spain
13NCT02509793August 1, 201830 September 2019A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)Huntington's DiseaseDrug: TetrabenazineWilliam Ondo, MDH. Lundbeck A/SRecruiting18 Years80 YearsAll20Phase 4United States
14EUCTR2018-000203-16-ES18/06/201820 August 2018Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements.Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements.Chorea movements associated with Huntington's Disease
MedDRA version: 20.0 Level: LLT Classification code 10020469 Term: Huntington's chorea System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Calvan® 100 mg
Pharmaceutical Form: Tablet
INN or Proposed INN: BEVANTOLOL HYDROCHLORIDE
CAS Number: 42864-78-8
Current Sponsor code: SOM3355
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
SOM BiotechAuthorisedFemale: yes
Male: yes
30Phase 2Spain
15NCT03252535January 15, 201823 April 2019Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's DiseaseDose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's DiseaseHuntington DiseaseBiological: Cellavita HD lower dose;Biological: Cellavita HD higher dose;Other: PlaceboAzidus BrasilCellavita Pesquisa Científica LtdaRecruiting21 Years65 YearsAll35Phase 2Brazil
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2017-002471-25-DE10/01/20184 December 2018An extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the study drug, RO7234292 (ISIS 443139), in patients who participated in prior investigational studies of RO7234292An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington’s Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)Early Manifest Huntington's Disease
MedDRA version: 20.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Code: Ro 723-4292/F02
Pharmaceutical Form: Solution for injection
INN or Proposed INN: n.a.
CAS Number: 1709886-74-7
Current Sponsor code: RO7234292
Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 6-
F.Hoffmann La-Roche LtdAuthorisedFemale: yes
Male: yes
46Phase 2Canada;Germany
17NCT03342053November 27, 20174 November 2019A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)Huntington's DiseaseDrug: RO7234292 (RG6042)Hoffmann-La RocheNot recruiting25 YearsN/AAll46Phase 2Canada;Germany;United Kingdom
18NCT02728115October 16, 201723 April 2019Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's DiseaseFirst in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's DiseaseHuntington DiseaseBiological: Cellavita HD Lower Dose;Biological: Cellavita HD Higher doseAzidus BrasilCellavita Pesquisa Científica Ltda;Azidus Brasil Scientific Research and Development LtdaNot recruiting21 Years65 YearsMale6Phase 1Brazil
19NCT03296176October 9, 201716 December 2017Metabolomic Study in Huntington's Disease (METABO-HD)Metabolomic Study in Huntington's DiseaseHuntington DiseaseBiological: blood sampleUniversity Hospital, AngersRecruiting20 Years70 YearsAll150N/AFrance
20NCT03225833July 17, 201722 July 2019Safety and Tolerability of WVE-120101 in Patients With Huntington's DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's DiseaseHuntington's DiseaseDrug: WVE-120101;Drug: PlaceboWave Life Sciences Ltd.Recruiting25 Years65 YearsAll48Phase 1/Phase 2Australia;Canada;Denmark;Poland;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT03225846July 17, 201722 July 2019Safety and Tolerability of WVE-120102 in Patients With Huntington's DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's DiseaseHuntington's DiseaseDrug: WVE-120102;Drug: PlaceboWave Life Sciences Ltd.Recruiting25 Years65 YearsAll48Phase 1/Phase 2Australia;Canada;Denmark;Poland;United Kingdom
22NCT03515213April 27, 201718 March 2019Safety and Efficacy of Fenofibrate as a Treatment for Huntington's DiseaseA Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's DiseaseHuntington DiseaseDrug: Fenofibrate;Drug: PlaceboUniversity of California, IrvineNot recruiting18 YearsN/AAll20Phase 2United States
23NCT03019289April 19, 201718 March 2019A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's DiseaseA Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's DiseaseHealth Volunteers, Huntington DiseaseDrug: pridopidine (90 mg)Prilenia Therapeutics Development Ltd.Not recruiting25 YearsN/AMale23Phase 1Germany
24EUCTR2016-003730-25-NL14/02/201712 February 2018A study to assess the safety and efficacy of a new medicine SBT-020 in patients with Early Stage Huntington’s Disease.A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington’s Disease. - SBT-020 in HDHuntington's Disease
MedDRA version: 20.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: SBT-020
Product Code: SBT-020
Pharmaceutical Form: Lyophilisate for solution for injection
INN or Proposed INN: SBT-020
CAS Number: 1795737-00-6
Current Sponsor code: SBT-020-01
Other descriptive name: SS-20
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 5-25
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Stealth Bio Therapeutics IncNot RecruitingFemale: yes
Male: yes
24Phase 2Netherlands
25NCT02507284May 10, 20164 November 2019Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's DiseaseAn Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)Irritable Mood;Huntington's DiseaseDrug: SRX246;Drug: PlaceboAzevan PharmaceuticalsNational Institute of Neurological Disorders and Stroke (NINDS);NeuroNEXT NetworkNot recruiting18 YearsN/AAll106Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT02907294March 201626 September 2016Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy VolunteersRandomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy VolunteersHuntington DiseaseDrug: PBF-999 / 160 mg;Drug: PBF-999 / 320 mg;Drug: PlaceboPalobiofarma SLFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauNot recruiting18 Years45 YearsBoth8Phase 1Spain
27EUCTR2014-005112-42-NL11/12/201529 January 2018A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)Huntington's disease
MedDRA version: 20.0 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: Triheptanoin
Product Code: UX007
Pharmaceutical Form: Oral solution
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use
INSERMAuthorisedFemale: yes
Male: yes
100Phase 2Netherlands
28NCT02494778September 24, 201518 March 2019A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's DiseaseA Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)Huntington's DiseaseDrug: PridopidinePrilenia Therapeutics Development Ltd.Not recruiting21 YearsN/AAll248Phase 2United States;Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;Denmark
29NCT02519036August 6, 201511 June 2019Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's DiseaseA Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's DiseaseHuntington's DiseaseDrug: ISIS 443139 10 mg;Drug: ISIS 443139 30 mg;Drug: ISIS 443139 60 mg;Drug: ISIS 443139 90 mg;Drug: ISIS 443139 120 mg;Other: PlaceboIonis Pharmaceuticals, Inc.Not recruiting25 Years65 YearsAll46Phase 1/Phase 2Canada;Germany;United Kingdom
30NCT02336633July 20152 September 2019Resveratrol and Huntington DiseaseMetabolic Intervention Using Resveratrol in Patients With Huntington DiseaseHuntington DiseaseDietary Supplement: Resveratrol;Other: PlaceboAssistance Publique - Hôpitaux de ParisNot recruiting18 YearsN/AAll102N/AFrance
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT02481674July 20156 May 2019A Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503)A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503Huntington's DiseaseDrug: VX15/2503;Drug: PlaceboVaccinex Inc.Huntington Study GroupNot recruiting21 YearsN/AAll301Phase 2United States;Canada
32NCT02453061June 29, 201529 July 2019A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's DiseaseA Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's DiseaseHuntington DiseaseDrug: Triheptanoin oil;Drug: PlaceboInstitut National de la Santé Et de la Recherche Médicale, FranceUltragenyx Pharmaceutical IncNot recruiting18 YearsN/AAll100Phase 2France;Netherlands
33NCT02342548February 25, 201511 June 2018Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021Huntington's DiseaseDrug: 20 mg BID of PF-02545920PfizerNot recruiting30 Years66 YearsAll188Phase 2United States;Canada;Germany;Poland;United Kingdom
34NCT02215616November 24, 201415 October 2018A Clinical Study in Subjects With Huntington's Disease to Assess Efficacy and Safety of Three Oral Doses of LaquinimodA Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's DiseaseHuntington's DiseaseDrug: Laquinimod;Drug: PlaceboTeva Branded Pharmaceutical Products, R&D Inc.Not recruiting21 Years55 YearsAll352Phase 2United States;Canada;Czechia;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;Czech Republic;France;India;Israel
35NCT02231580September 1, 201428 January 2019Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease PatientsA Dose Escalation, Proof of Concept, Phase IIa Study to Investigate the Safety and Tolerability, the Pharmacokinetic and the Pharmacodynamic of BN82451B, Administered Twice Daily Over 4 Weeks, in Male Patients With Huntington's DiseaseHuntington's DiseaseDrug: Placebo;Drug: BN82451BIpsenNot recruiting20 Years70 YearsMale17Phase 2Germany
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT01834053September 201419 February 2015Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical TrialHuntington DiseaseBiological: autologous Stem CellChaitanya Hospital, PuneRecruiting35 Years44 YearsBoth50Phase 1/Phase 2India
37NCT02197130September 201416 December 2017Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's DiseaseA Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's DiseaseHuntington's DiseaseDrug: PF-02545920;Other: PlaceboPfizerNot recruiting30 Years65 YearsAll272Phase 2United States;Canada;Germany;Poland;United Kingdom
38NCT02208934September 201411 April 2016Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male VolunteersStudy To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male VolunteersHuntington's DiseaseDrug: PBF-999;Drug: PlaceboFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauPalo Biofarma, S.LNot recruiting18 Years45 YearsMale32Phase 1Spain
39EUCTR2013-002899-41-DE28/04/201422 May 2017Study to assess the effects of BN82451B and how it is absorbed, distributed and eliminated in the body, when it is given for 4 weeks to men suffering from Hungtington's diseaseA dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and the pharmacodynamic of BN82451B, administered twice daily over 4 weeks, in male patients with Huntington’s diseaseHuntington's disease
MedDRA version: 18.1 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: BN8251B
Pharmaceutical Form: Capsule
INN or Proposed INN: N/A
CAS Number: 918656-59-4
Current Sponsor code: BN82451B
Other descriptive name: BN82451B
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: BN8251B
Pharmaceutical Form: Capsule
INN or Proposed INN: N/A
CAS Number: 918656-59-4
Current Sponsor code: BN82451B
Other descriptive name: BN82451B
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Ipsen PharmaNot RecruitingFemale: no
Male: yes
Phase 2Germany
40NCT02006472February 28, 201418 March 2019A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's DiseaseA Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's DiseaseHuntington's DiseaseDrug: Pridopidine;Other: PlaceboPrilenia Therapeutics Development Ltd.European Huntington's Disease Network;Huntington Study GroupNot recruiting21 YearsN/AAll408Phase 2United States;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41EUCTR2013-001888-23-GB22/01/20141 December 2014A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease.A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s DiseaseHuntington’s disease
MedDRA version: 17.1 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
Pharmaceutical Form: Capsule
INN or Proposed INN: pridopidine
CAS Number: 882737-42-0
Current Sponsor code: TV-7820
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 22.5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Pridopidine
Product Code: TV-7820
Pharmaceutical Form: Capsule
INN or Proposed INN: pridopidine
CAS Number: 882737-42-0
Current Sponsor code: TV-7820
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 45-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Teva Branded Pharmaceutical Products R&D, IncAuthorisedFemale: yes
Male: yes
400Phase 2United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands
42EUCTR2013-002545-10-SE08/01/201427 June 2016An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy.An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. - OSU6162Open1309Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Code: OSU6162 similar to (-)-OSU 6162
Pharmaceutical Form: Coated tablet
A. Carlsson Research ABAuthorisedFemale: yes
Male: yes
240Phase 2Sweden
43NCT01897896November 12, 201316 December 2017Alternatives for Reducing Chorea in HDAn Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington DiseaseChorea Associated With Huntington DiseaseDrug: SD-809Auspex Pharmaceuticals, Inc.Not recruiting18 YearsN/AAll119Phase 3United States;Canada;Australia
44NCT01806896September 201316 December 2017Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's DiseaseA Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of Pf-02545920 In Subjects With Early Huntington's DiseaseHuntington's DiseaseDrug: PF-02545920;Drug: PlaceboPfizerNot recruiting18 Years70 YearsAll37Phase 2France
45NCT01795859August 5, 201316 December 2017First Time Use of SD-809 in Huntington DiseaseA Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington DiseaseChoreaDrug: SD-809;Drug: PlaceboTeva Pharmaceutical IndustriesNot recruiting18 YearsN/AAll90Phase 3United States;Australia;Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT01882062May 201319 October 2017Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington DiseaseHuntington DiseaseDrug: Triheptanoin 1g/kg/dayInstitut National de la Santé Et de la Recherche Médicale, FranceNot recruiting18 YearsN/AAll10Phase 2France
47NCT01834911March 201311 June 2018Effect of Tetrabenazine on Stroop Interference in HDEffect of Tetrabenazine on Stroop Interference in Huntington DiseaseHuntington DiseaseDrug: Tetrabenazine withdrawalNew York Medical CollegeNot recruiting18 YearsN/AAll2Phase 4United States
48NCT01696708December 6, 201216 December 2017Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington DiseaseStudy of the Brain Energy Profile Evolution, Using 31Phosphorus-Nuclear Magnetic Resonance Spectroscopy, at Different Stages of Huntington DiseaseHuntington DiseaseOther: 31-Phosphorus RMN SpectroscopyInstitut National de la Santé Et de la Recherche Médicale, FranceNot recruiting18 YearsN/AAll50N/AFrance
49NCT01914965June 201219 February 2015Apathy Cure Through Bupropion in Huntington's DiseaseA Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's DiseaseApathy;Huntington's DiseaseDrug: Bupropion;Drug: PlaceboCharite University, Berlin, GermanyUniversity of Ulm;Ruhr University of Bochum;University Hospital MuensterNot recruiting25 Years75 YearsBoth40Phase 2Germany
50NCT01590888April 201219 October 2017Effect of PBT2 in Patients With Early to Mid Stage Huntington DiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington DiseaseHuntington DiseaseDrug: PBT2;Drug: PlaceboPrana Biotechnology LimitedNot recruiting25 YearsN/AAll109Phase 2United States;Australia
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT01573819November 24, 201116 December 2017A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278Huntington DiseaseDrug: GSK356278;Drug: PlaceboGlaxoSmithKlineNot recruiting18 Years65 YearsAll36Phase 1Netherlands
52NCT01602900November 22, 201116 December 2017Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's DiseaseAn Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s)Huntington DiseaseDrug: GSK356278;Drug: RolipramGlaxoSmithKlineNot recruiting22 Years55 YearsMale8Phase 1United Kingdom
53NCT01485965November 201119 February 2015A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington DiseaseA Phase 1b, Open-label, Parallel-group Study in Subjects With Huntington Disease to Assess the Safety, Tolerability, and Fed/Fasted Pharmacokinetics of Repeated Oral Doses of SEN0014196Huntington's DiseaseDrug: SEN0014196Siena Biotech S.p.A.Not recruiting25 Years65 YearsBoth26Phase 1United States
54NCT01521585November 20117 December 2015A Phase II Safety and Tolerability Study With SEN0014196A Double-blind, Placebo-controlled Study in Huntington's Disease Patients to Determine the Safety and Tolerability of SEN0014196Huntington's DiseaseDrug: SEN0014196;Drug: PlaceboSiena Biotech S.p.A.Not recruiting30 Years70 YearsBoth144Phase 2Germany
55EUCTR2011-001131-23-DE21/09/20112 December 2013A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/AHuntington's disease
MedDRA version: 14.1 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: SEN0014196
Product Code: SEN0014196
Pharmaceutical Form: Tablet
INN or Proposed INN: selisistat
CAS Number: 49843-98-3
Current Sponsor code: SEN0014196
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: SEN0014196
Product Code: SEN0014196
Pharmaceutical Form: Tablet
INN or Proposed INN: selisistat
CAS Number: 49843-98-3
Current Sponsor code: SEN0014196
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Siena Biotech SpANot RecruitingFemale: yes
Male: yes
144Germany;Italy;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT01458470September 201119 February 2015A Trial of Memantine as Symptomatic Treatment for Early Huntington DiseaseA Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb StudyHuntington DiseaseDrug: Memantine;Other: PlaceboUniversity of British ColumbiaHuntington Society of Canada;Huntington Study GroupNot recruiting18 Years75 YearsBoth19Phase 2Canada
57NCT01306929March 1, 201118 March 2019Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington DiseaseA Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).Huntington DiseaseDrug: pridopidinePrilenia Therapeutics Development Ltd.Not recruitingN/AN/AAll235Phase 2United States;Canada
58NCT02101957October 201019 February 2015Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)Huntington's DiseaseDrug: RP103;Drug: PlaceboUniversity Hospital, AngersNot recruiting18 Years65 YearsBoth96Phase 2/Phase 3France
59EUCTR2009-018119-14-GB23/07/20107 January 2013Huntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine studyHuntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine studyHuntington's Disease
MedDRA version: 14.1 Level: PT Classification code 10070668 Term: Huntington's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: Hyperium
Product Name: Rilmenidine
Pharmaceutical Form: Tablet
INN or Proposed INN: Rilmenidine
CAS Number: 54187-04-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1mg-
Cambridge University Hospitals NHS Foundation Trust and University of CambridgeAuthorisedFemale: yes
Male: yes
16United Kingdom
60EUCTR2010-019444-39-FR18/06/201019 March 2012Essai multicentrique de traitement de la maladie de Huntington par la cystéamine - CYST-HDEssai multicentrique de traitement de la maladie de Huntington par la cystéamine - CYST-HDMaladie de Huntington.
MedDRA version: 12.1 Level: LLT Classification code 10020469 Term: Huntington's chorea
Product Name: Cysteamine Bitartrate
Product Code: RP 103
Pharmaceutical Form: Capsule, hard
CAS Number: 27761-19-9
Concentration unit: Other
Concentration type: equal
Concentration number: 221mg/capsule-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Centre Hospitalier Universitaire d'AngersAuthorisedFemale: yes
Male: yes
France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61EUCTR2009-018123-32-DE07/06/20104 March 2013HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHuntington disease
MedDRA version: 12.1 Level: LLT Classification code 10020469 Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Dimebon dihydrochloride
CAS Number: 97657-92-6
Current Sponsor code: Dimebon
Other descriptive name: Dimebon dihydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Product Name: Dimebon
Product Code: Dimebon
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Dimebon dihydrochloride
CAS Number: 97657-92-6
Current Sponsor code: Dimebon
Other descriptive name: Dimebon dihydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Medivation, IncNot RecruitingFemale: yes
Male: yes
350Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden
62NCT01411163April 201019 February 2015Premanifest Huntington's Disease Extension Study II: Creatine Safety & TolerabilityPremanifest Huntington's Disease Extension Study II: Creatine Safety & TolerabilityHuntington's DiseaseDrug: Creatine monohydrateMassachusetts General HospitalNational Institutes of Health (NIH)Not recruiting26 YearsN/ABoth24Phase 2United States
63NCT00920699February 201016 December 2017Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's DiseaseHuntington's DiseaseDrug: CoQ10Johns Hopkins UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting18 YearsN/AAll90Phase 2United States
64NCT01085266February 201024 October 2016An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington DiseaseHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington DiseaseHuntington DiseaseDrug: Dimebon (latrepirdine)Medivation, Inc.Pfizer;PfizerNot recruiting30 YearsN/ABoth362Phase 3
65EUCTR2009-011800-44-GB07/10/200914 August 2012A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZONA Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZONHuntington disease
MedDRA version: 9.1 Level: LLT Classification code 10020469 Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Dimebon dihydrochloride
CAS Number: 97657-92-6
Current Sponsor code: Dimebon
Other descriptive name: Dimebon dihydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: Dimebon
Product Code: Dimebon
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Dimebon dihydrochloride
CAS Number: 97657-92-6
Current Sponsor code: Dimebon
Other descriptive name: Dimebon dihydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Medivation, IncNot RecruitingFemale: yes
Male: yes
350Phase 3Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66NCT00975481October 200919 October 2017A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug UsersA Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug UsersAlzheimer's Disease;Huntington's DiseaseDrug: dimebon;Drug: placebo;Drug: alprazolamPfizerMedivation, Inc.Not recruiting18 Years55 YearsAll36Phase 1Canada
67NCT00988624October 200919 February 2015A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)Alzheimer's Disease;Huntington DiseaseDrug: Dimebon IR Tablet;Drug: Dimebon MR1;Drug: Dimebon MR2;Drug: Dimebon MR3;Drug: Dimebon MR4PfizerMedivation, Inc.Not recruiting18 Years55 YearsBoth20Phase 1United States
68NCT00990613October 200919 February 2015A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The SkinA Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older AdultsAlzheimer's Disease;Huntington's DiseaseDrug: Dimebon IR;Drug: Dimebon TransdermalPfizerMedivation, Inc.Not recruiting50 Years85 YearsBoth19Phase 1United States
69NCT01521832October 200919 February 2015Escalating Dose Study in Healthy Volunteers With SEN0014196A Phase I, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study Consisting of Single and Multiple Oral Dose Escalation to Determine, Safety, Tolerability and Pharmacokinetics of SEN0014196Huntington's DiseaseDrug: SEN0014196Siena Biotech S.p.A.Not recruiting18 Years65 YearsBoth88Phase 1United Kingdom
70EUCTR2009-011743-39-DE18/09/200912 November 2012Efficacy, Safety and Tolerability of AFQ056 in Patients with Huntington's Disease in Reducing ChoreaA multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing choreaHuntington's disease
MedDRA version: 13.1 Level: LLT Classification code 10020469 Term: Huntington's chorea System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AFQ056
Product Code: AFQ056
Pharmaceutical Form: Capsule, hard
CAS Number: 543906-09-8
Current Sponsor code: AFQ056
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Product Name: AFQ056
Product Code: AFQ056
Pharmaceutical Form: Capsule, hard
CAS Number: 543906-09-8
Current Sponsor code: AFQ056
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Novartis Pharma Services AGNot RecruitingFemale: yes
Male: yes
60United States;Germany;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71NCT00712426September 200930 March 2015Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)Huntington's DiseaseDrug: Creatine Monohydrate;Drug: PlaceboMassachusetts General HospitalUniversity of Rochester;National Center for Complementary and Integrative Health (NCCIH)Not recruiting18 YearsN/ABoth553Phase 3United States;Australia;Canada;New Zealand
72NCT00980694September 200913 June 2016Bioavailability of Ubiquinol in Huntington DiseaseBioavailability of Ubiquinol in Huntington DiseaseHuntington DiseaseDietary Supplement: ubiquinolUniversity of RochesterKaneka CorporationNot recruiting18 YearsN/ABoth6Phase 1United States
73NCT00920946July 200924 October 2016A Safety and Efficacy Study of Dimebon in Patients With Huntington DiseaseA Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients With Mile-to-Moderate Huntington DiseaseHuntington DiseaseDrug: Dimebon;Other: PlaceboMedivation, Inc.Pfizer;PfizerNot recruiting30 YearsN/ABoth403Phase 3United States;Australia;Canada;Denmark;Germany;Sweden;United Kingdom
74NCT00931073July 200919 February 2015A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 MetabolizersA Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon [PF-01913539] In Healthy CYP2D6 EM And PM SubjectsAlzheimer's Disease;Huntington's DiseaseDrug: Dimebon alone;Drug: Dimebon + Ketoconazole;Drug: Dimebon + OmeprazolePfizerMedivation, Inc.Not recruiting18 Years55 YearsBoth24Phase 1United States
75NCT00970229July 200916 December 2017Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy ControlsParkinson Disease;Huntington DiseaseDrug: [123I]MNI-420Institute for Neurodegenerative DisordersNot recruiting18 YearsN/AAll19Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76NCT00907595May 200919 February 2015Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With RamelteonTreating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled TrialHuntington's Disease;Parkinson's Disease;Dementia With Lewy Bodies;Sleep Disorders;Circadian DysregulationDrug: Ramelteon;Drug: PlaceboMassachusetts General HospitalNot recruiting20 Years90 YearsBoth0N/AUnited States
77NCT01411150May 200919 February 2015Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension StudyPremanifest Huntington's Disease: Creatine Safety & Tolerability Extension StudyHuntington's DiseaseDrug: Creatine MonohydrateMassachusetts General HospitalNational Institutes of Health (NIH)Not recruiting26 YearsN/ABoth38Phase 2United States
78NCT00632645April 200929 January 2018Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and TiaprideNeuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study.Huntington DiseaseDrug: Olanzapine;Drug: Xenazine;Drug: TiapridalAssistance Publique - Hôpitaux de ParisNot recruiting18 YearsN/AAll180Phase 3France
79NCT00870974March 200916 December 2017A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric ConditionsEvaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric ConditionsParkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive ImpairmentDrug: [18F]FPEBInstitute for Neurodegenerative DisordersNot recruiting18 Years85 YearsAll48Phase 1United States
80NCT00824590February 200919 February 2015A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal FunctionA Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal FunctionAlzheimer's Disease;Huntington's DiseaseDrug: DimebonPfizerMedivation, Inc.Not recruiting18 Years75 YearsBoth20Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
81NCT00825084February 200919 February 2015A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy SubjectsA Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Parallel-Cohort, Single-Dose Escalation, And Multiple-Dose Titration Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy SubjectsAlzheimer's Disease;Huntington's DiseaseDrug: DimebonPfizerMedivation, Inc.Not recruiting18 Years55 YearsBoth45Phase 1United States
82NCT00827034February 200922 October 2018A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsA Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsAlzheimer's Disease;Huntington's DiseaseDrug: Warfarin;Drug: DimebonPfizerMedivation, Inc.Not recruiting18 Years55 YearsAll14Phase 1United States
83NCT00831506February 200919 February 2015Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy SubjectsA Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy SubjectsAlzheimer Disease;Huntington DiseaseDrug: digoxin;Drug: dimebonPfizerMedivation, Inc.Not recruiting18 Years55 YearsBoth12Phase 1United States
84NCT00788047November 200819 February 2015A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of DextromethorphanA Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy SubjectsHuntington Disease;Alzheimer DiseaseDrug: Dextromethorphan;Drug: Dimebon + DextromethorphanPfizerMedivation, Inc.Not recruiting18 Years55 YearsBoth14Phase 1United States
85NCT00724048October 20088 August 2016A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's DiseaseA Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)Huntington DiseaseDrug: ACR16 10 mg;Drug: ACR16 22.5 mg;Drug: ACR16 45 mg;Other: PlaceboTeva Pharmaceutical IndustriesNot recruiting30 YearsN/ABoth227Phase 2/Phase 3United States;Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
86EUCTR2007-002977-30-FR02/09/200819 March 2012Essai multicentrique évaluant l'effet de la cystéamine sur le BDNF sérique dans la maladie de Huntington. - BDNF-HDEssai multicentrique évaluant l'effet de la cystéamine sur le BDNF sérique dans la maladie de Huntington. - BDNF-HDMaladie de Huntigton (MH): maladie neurodégénérative d’origine génétique. Elle associe des troubles moteurs, psychiatriques et cognitifs (dégénérescence neuronale dans le striatum). Aucun traitement validé n’existe à ce jour.
MedDRA version: 9.1 Level: LLT Classification code 10020469 Term: Huntington's chorea
Trade Name: CYSTAGON
Product Name: CYSTAGON
Pharmaceutical Form: Capsule, hard
Centre Hospitalier Universitaire d'AngersAuthorisedFemale: yes
Male: yes
France
87NCT00665223April 20088 August 2016A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's DiseaseA Multicentre, Multinational, Randomized, Double-blind, Parallel-group Study Comparing ACR16 Versus Placebo for the Symptomatic Treatment of Huntington's DiseaseHuntington's DiseaseDrug: ACR16;Drug: PlaceboTeva Pharmaceutical IndustriesNot recruiting30 YearsN/ABoth437Phase 3Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
88NCT00608881March 200819 October 2017Coenzyme Q10 in Huntington's Disease (HD)Coenzyme Q10 in Huntington's Disease (HD)Huntington's DiseaseDrug: coenzyme Q10;Other: placeboMassachusetts General HospitalNational Institute of Neurological Disorders and Stroke (NINDS);University of RochesterNot recruiting16 YearsN/AAll609Phase 3United States;Australia;Canada
89EUCTR2007-004988-22-GB11/01/200818 September 2012A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)Huntington's Disease
MedDRA version: 9.1 Level: LLT Classification code 10020469 Term: Huntington's chorea
Product Name: ACR16
Product Code: ACR16
Pharmaceutical Form: Capsule, hard
Current Sponsor code: ACR16
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 45-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
NeuroSearch Sweden ABNot RecruitingFemale: yes
Male: yes
420Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria
90NCT00592995December 200719 February 2015Creatine Safety and Tolerability in Premanifest HD: PRECRESTCreatine Safety and Tolerability in Premanifest HD: PRECRESTHuntington DiseaseDrug: Creatine monohydrate;Drug: PlaceboMassachusetts General HospitalNot recruiting26 YearsN/ABoth64Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
91EUCTR2007-003293-25-GB20/11/200719 March 2012A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE - DIMONDA MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE - DIMONDHuntington's disease
MedDRA version: 9.1 Level: LLT Classification code 10020469 Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
Pharmaceutical Form: Tablet
CAS Number: 3613-73-8
Current Sponsor code: Dimebon
Other descriptive name: Dimebon Dihydrochloride
Concentration unit: % (W/W) percent weight/weight
Concentration type: equal
Concentration number: 18%-22%
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Medivation, Inc.AuthorisedFemale: yes
Male: yes
90Phase 2United Kingdom
92NCT00514774August 200719 February 2015Ursodiol in Huntington's DiseaseUrsodiol in Huntington's DiseaseHuntington DiseaseDrug: ursodiol;Drug: placeboOregon Health and Science UniversityHuntington Study Group;Huntington Society of CanadaNot recruiting18 YearsN/ABoth21Phase 1United States
93NCT00497159July 200719 February 2015A Study of the Novel Drug Dimebon in Patients With Huntington's DiseaseA Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's DiseaseHuntington's DiseaseOther: Placebo;Drug: DimebonMedivation, Inc.Huntington Study GroupNot recruiting29 YearsN/ABoth90Phase 2United States
94NCT00387270October 200619 February 2015Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's DiseaseA Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's DiseaseHuntington's DiseaseDrug: DimebonMedivation, Inc.Huntington Study GroupNot recruiting18 YearsN/ABoth9Phase 1/Phase 2United States
95NCT00277355April 200619 October 2017Pilot Study of Minocycline in Huntington's DiseaseA Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's DiseaseHuntington DiseaseDrug: minocycline;Drug: Matching placeboMerit CudkowiczFDA Office of Orphan Products DevelopmentNot recruiting18 YearsN/AAll114Phase 2/Phase 3United States;Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
96EUCTR2005-002088-98-GB07/11/20051 May 2012Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseFull title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseHUNTINGTON’S DISEASE
MedDRA version: 8.0 Level: LLT Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
Pharmaceutical Form: Capsule, soft
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Amarin Neuroscience LtdNot RecruitingFemale: yes
Male: yes
Portugal;Germany;United Kingdom;Spain;Italy
97NCT00271596November 200519 October 2017Citalopram to Enhance Cognition in HDA Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)Huntington Disease;Chorea;Executive DysfunctionDrug: 20mg daily citalopram;Drug: PlaceboUniversity of IowaNational Institute of Neurological Disorders and Stroke (NINDS);Cure Huntington's Disease Initiative (CHDI);University of Rochester;Mayo ClinicNot recruiting18 Years75 YearsAll33Phase 2United States
98NCT00368849November 200519 October 2017Atomoxetine and Huntington's DiseaseAtomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover StudyHuntington Disease;ChoreaDrug: atomoxetine;Drug: Matching PlaceboUniversity of IowaEli Lilly and CompanyNot recruiting18 Years65 YearsAll20Phase 2United States
99NCT00146211September 200519 February 2015TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's DiseaseA Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's DiseaseHuntington DiseaseDrug: Ethyl-EPA (Miraxion™)Amarin Neuroscience LtdHuntington Study GroupNot recruiting35 YearsN/ABoth300Phase 3United States;Canada
100NCT00212316August 200519 February 2015Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)Phenylbutyrate Development for Huntington's Disease (PHEND-HD): A Multi-Center, Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Tolerability of Phenylbutyrate in Subjects With Huntington's DiseaseHuntington's DiseaseDrug: sodium phenylbutyrateUniversity of RochesterHP Therapeutics Foundation;Massachusetts General Hospital;Columbia University;University of Iowa;University of California, San Diego;University of Kansas;University of Alabama at Birmingham;Johns Hopkins UniversityNot recruiting18 YearsN/ABoth60Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
101NCT01412151April 200519 October 2017Creatine Safety & Tolerability in Huntington's DiseaseCreatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HDHuntington's Disease (HD)Drug: Creatine monohydrateMassachusetts General HospitalNot recruiting18 YearsN/AAll10Phase 2United States
102NCT00095355October 200419 February 2015Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's DiseaseStimulation of Tyrosine Kinase and ERK Signaling Pathways in Huntington's DiseaseHuntington's DiseaseDrug: Lithium;Drug: DivalproexNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth35Phase 2United States
103EUCTR2004-000394-60-SE30/06/200419 March 2012A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington diseaseA randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington diseaseACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CNS, depending on the initial level of dopaminergic activity. The stabilizing feature of such compounds is illustrated by their interaction with dopaminergic agonists.Product Name: ACR16
Product Code: ACR16
Pharmaceutical Form: Capsule*
CAS Number: 346688-38-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
A. Carlsson Research ABNot RecruitingFemale: yes
Male: yes
60Phase 2Denmark;Sweden
104NCT00652457September 200319 February 2015Study of Memantine to Treat Huntington's DiseaseA Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's DiseaseHuntington's DiseaseDrug: MemantineUniversity of California, San DiegoForest LaboratoriesRecruiting18 YearsN/ABoth60Phase 4United States
105NCT00190450January 200216 December 2017MIG-HD: Multicentric Intracerebral Grafting in Huntington's DiseaseMulticentric Intracerebral Grafting in Huntington's DiseaseHuntington DiseaseBiological: graft intracerebral of foetal neuronsAssistance Publique - Hôpitaux de ParisNot recruiting18 Years65 YearsAll54Phase 2France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
106NCT00026988October 200119 February 2015Creatine Therapy for Huntington's DiseaseCreatine Therapy for Huntington's DiseaseHuntington's DiseaseDrug: CreatineNational Center for Complementary and Integrative Health (NCCIH)Not recruiting18 YearsN/ABoth64Phase 1/Phase 2United States
107NCT00029874September 20017 April 2015Minocycline in Patients With Huntington's DiseaseMinocycline Dosing and Safety in Huntington's DiseaseHuntington's DiseaseDrug: MinocyclineFDA Office of Orphan Products DevelopmentNot recruiting18 YearsN/ABoth63Phase 1/Phase 2United States
108NCT00219804January 200019 February 2015Efficacy and Safety of Tetrabenazine in ChoreaA Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's ChoreaHuntington's DiseaseDrug: tetrabenazine or placeboPrestwick PharmaceuticalsNot recruiting18 YearsN/ABothPhase 3
109NCT00277602November 199919 February 2015Riluzole in Huntington's DiseaseA Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's DiseaseHuntington DiseaseDrug: RiluzoleSanofiNot recruiting25 Years65 YearsBoth537Phase 3
110NCT00001930April 199919 February 2015Treatment of Huntington's Chorea With AmantadineNMDA-Receptor Blockade in Huntington's ChoreaChorea;Huntington's DiseaseDrug: AmantadineNational Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth25Phase 2United States

先頭へ